232 related articles for article (PubMed ID: 6640524)
21. Intra- and interspecies reactivity of human and mouse natural killer (NK) cells.
Hansson M; Bakacs KK; Kiessling R; Klein G
J Immunol; 1978 Jul; 121(1):6-12. PubMed ID: 78947
[TBL] [Abstract][Full Text] [Related]
22. [Effects of phenytoin on cell-mediated immunity].
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Mogami H
No To Shinkei; 1987 Oct; 39(10):931-6. PubMed ID: 3501727
[TBL] [Abstract][Full Text] [Related]
23. Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2).
Mills GB; Paetkau V
J Immunol; 1980 Nov; 125(5):1897-903. PubMed ID: 6159395
[TBL] [Abstract][Full Text] [Related]
24. Suppression and abrogation of suppression of induced nonspecific cytotoxicity against tumor cells.
Egawa K; Tanino T
Jpn J Exp Med; 1985 Aug; 55(4):143-53. PubMed ID: 2935654
[TBL] [Abstract][Full Text] [Related]
25. Lectin-dependent cell-mediated cytotoxicity: assessment of cytotoxic reactivity following challenge with syngeneic tumors.
Laux DC; Parker BM; DiSciullo SO; Petrarca MA; McAllister CG
J Natl Cancer Inst; 1984 Mar; 72(3):667-72. PubMed ID: 6583449
[TBL] [Abstract][Full Text] [Related]
26. Studies on natural killer (NK) cells. III. The effects of in vitro culture on spontaneous cytotoxicity of murine spleen cells.
Bartlett SP; Burton RC
J Immunol; 1982 Mar; 128(3):1070-5. PubMed ID: 7057032
[TBL] [Abstract][Full Text] [Related]
27. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
28. Suppression of the cytotoxic response of mouse lymphocytes to syngeneic tumor cells by tumor-promoting phorbol ester.
Fredrickson GG; Bennett M
Cancer Res; 1982 Sep; 42(9):3601-6. PubMed ID: 7105034
[TBL] [Abstract][Full Text] [Related]
29. Induction of NKCF-like activity in mixed lymphocyte-tumor cell culture: direct involvement of mycoplasma infection of tumor cells.
Wayner EA; Brooks CG
J Immunol; 1984 Apr; 132(4):2135-42. PubMed ID: 6230401
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer cells: in vitro and in vivo studies.
Mazumder A
Lymphokine Res; 1985; 4(3):215-20. PubMed ID: 3897730
[TBL] [Abstract][Full Text] [Related]
31. H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.
Sentman CL; Olsson MY; Salcedo M; Höglund P; Lendahl U; Käre K
J Immunol; 1994 Dec; 153(12):5482-90. PubMed ID: 7989750
[TBL] [Abstract][Full Text] [Related]
32. Natural killing of xenogeneic cells mediated by the mouse Ly-49D receptor.
Nakamura MC; Naper C; Niemi EC; Spusta SC; Rolstad B; Butcher GW; Seaman WE; Ryan JC
J Immunol; 1999 Nov; 163(9):4694-700. PubMed ID: 10528166
[TBL] [Abstract][Full Text] [Related]
33. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
34. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
35. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
36. Natural cytostatic cells have a broader range of antitumor activity than natural killer cells.
Kato M; Kawauchi H; Taniguchi K; Katsuki T; Nomoto K
J Clin Lab Immunol; 1985 Jan; 16(1):47-51. PubMed ID: 3872372
[TBL] [Abstract][Full Text] [Related]
37. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
38. Splenocytes cultured in low concentrations of IL-2 generate NK cell specificities toward syngenic and allogenic targets.
Nissen MH; Jeppesen M; Claesson MH
Cell Immunol; 2000 Jul; 203(1):47-54. PubMed ID: 10915561
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
